Ripple Effect: Repackaged Losartan Recalled Due to Impurity Ripple Effect: Repackaged Losartan Recalled Due to Impurity

Legacy Pharmaceutical recalls 43 repackaged lots of losartan because of the presence of the probable carcinogen N-nitroso-N-methyl-4-aminobutyric acid (NMBA) in the active pharmaceutical ingredient.News Alerts
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Alert Source Type: news